Oral Session 1-7D Multiple Myeloma: Novel Agents

[OS1-7D-1] Phase 1/2 study of anti-CD38 antibody isatuximab monotherapy for RRMM in Japanese patients

Masaki Ri¹, Kazutaka Sunami², Morio Matsumoto³, Chihiro Shimazaki⁴, Hideki Asaoku⁵, Dai Maruyama⁶, Hirohiko Shibayama⁷, Kenichi Ishizawa⁸, Hiroyuki Takamatsu⁹, Takashi Ikeda¹⁰, Hitomi Kaneko¹¹, Michihiro Uchiyama¹², Toru Kiguchi¹³, Satoshi Iyama¹⁴, Hirokazu Murakami¹⁵, Toru Sasaki¹⁶, Keisuke Tada¹⁶, Kenshi Suzuki¹⁷, Shinsuke Iida¹ (1.Hematol. & Oncol., Nagoya City University, Nagoya, Japan, 2.National Hospital Organization Okayama Medical Center, Okayama, Japan, 3.National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan, 4.Japan Community Healthcare Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan, 5.Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, 6.National Cancer Center Hospital, Tokyo, Japan, 7.Osaka University Graduate School of Medicine, Osaka, Japan, 8.Yamagata University Faculty of Medicine, Yamagata, Japan, 9.Kanazawa University Hospital, Kanazawa, Japan, 10.Shizuoka Cancer Center, Shizuoka, Japan, 11.Japanese Red Cross Osaka Hospital, Osaka, Japan, 12.Japanese Red Cross Society Suwa Hospital, Suwa, Japan, 13.Chugoku Central Hospital, Fukuyama, Japan, 14.Sapporo Medical University School of Medicine, Sapporo, Japan, 15.Gunma University Graduate School of Health Sciences, Maebashi, Japan, 16.Sanofi K.K., 17.Japanese Red Cross Medical Center, Tokyo, Japan)